Literature DB >> 28954617

Diagnosing, monitoring and managing behavioural variant frontotemporal dementia.

Olivier Piguet1, Fiona Kumfor2, John Hodges2.   

Abstract

Behavioural variant frontotemporal dementia is characterised by insidious changes in personality and interpersonal conduct that reflect progressive disintegration of the neural circuits involved in social cognition, emotion regulation, motivation and decision making. The underlying pathology is heterogeneous and classified according to the presence of intraneuronal inclusions of tau, TDP-43 or, occasionally, fused in sarcoma proteins. Biomarkers to detect these histopathological changes in life are increasingly important with the development of disease-modifying drugs. A number of gene abnormalities have been identified, the most common being an expansion in the C9orf72 gene, which together account for most familial cases. The 2011 international consensus criteria propose three levels of diagnostic certainty: possible, probable and definite. Detailed history taking from family members to elicit behavioural features underpins the diagnostic process, with support from neuropsychological testing designed to detect impairment in decision making, emotion processing and social cognition. Brain imaging is important for increasing the level of diagnosis certainty over time. Carer education and support remain of paramount importance.

Entities:  

Keywords:  Dementia; Neurocognitive disorders; Neuroimaging

Mesh:

Year:  2017        PMID: 28954617     DOI: 10.5694/mja16.01458

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Interactions between decision-making and emotion in behavioral-variant frontotemporal dementia and Alzheimer's disease.

Authors:  Aurélie L Manuel; Daniel Roquet; Ramon Landin-Romero; Fiona Kumfor; Rebekah M Ahmed; John R Hodges; Olivier Piguet
Journal:  Soc Cogn Affect Neurosci       Date:  2020-07-30       Impact factor: 3.436

2.  A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.

Authors:  Lucy Vivash; Charles B Malpas; Leonid Churilov; Mark Walterfang; Amy Brodtmann; Olivier Piguet; Rebekah M Ahmed; Ashley I Bush; Christopher M Hovens; T Kalincik; David Darby; Dennis Velakoulis; Terence J O'Brien
Journal:  BMJ Open       Date:  2020-11-16       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.